Longxiao Powder Veterinary Grade API is a pharmaceutical-grade active substance supplied as a powder for formulation into tablets, injections, capsules, powders, granules, premixes, and solutions. The designation is an API classification rather than a finished veterinary medicinal product; therefore, each batch must be released against identity, assay, related substances, loss on drying, residue on ignition, heavy metals, residual solvents, and microbial quality before use. For veterinary pharmaceutical applications, the quality framework includes the relevant pharmacopoeial monograph where available, supplemented by VICH GL18 for residual solvents and a validated in-house HPLC assay when a public monograph is absent. The product differs from a feed-grade or technical-grade powder because the batch documentation must be suitable for pharmaceutical processing, not only for feed additive assay control. Published numerical specification ranges for this specific API configuration are limited; formulation work should therefore be based on the vendor certificate of analysis and product-specific forced-degradation data rather than assumed ranges.

When the Powder Is Evaluated for Direct Compression and Encapsulation

For tablet and capsule operations, the as-received particle size distribution governs content uniformity, segregation tendency, and compaction behaviour. If the API is a low-dose component in a tablet core with a target active content below 5.0 mg per unit, direct compression is generally unsuitable unless the powder is micronised and co-processed with a suitable carrier. A wet-granulation route is preferred for such low-dose formulations because it locks the active substance into a granule matrix and reduces segregation in the tablet press feed frame. Blend uniformity is assessed by sampling from not fewer than 10 locations with a thief sampler and assaying by a validated HPLC method. Finished tablet content uniformity is measured according to Ph. Eur. 2.9.40 or USP <905>; an acceptance value of ≤ 15.0 is commonly applied unless the product is a high-dose formulation where mass variation may be justified.

Bulk density and tapped density should be recorded according to Ph. Eur. 2.9.34 or USP <616>. The Carr index and Hausner ratio are then calculated to flag flow problems. If the Carr index exceeds 25, the powder may require granulation or the addition of 0.5–1.0 % w/w colloidal silicon dioxide. The exact glidant level must be confirmed by shear cell testing on a rotational shear cell, because excessive glidant can reduce tablet tensile strength. Encapsulation of Longxiao Powder is usually carried out on a dosator or tamping pin machine; powder bed depth and compression settings are adjusted to achieve a target weight variation below ± 5.0 % for capsules with average fill weight above 300 mg per USP <905> or Ph. Eur. 2.9.40. If the API is cohesive, a dry granulation step by roller compaction with a roll force of 4–12 kN/cm may be used, but this range is equipment dependent and must be optimised on the specific roller compactor. Published data for the Longxiao Powder compaction behaviour are limited; feasibility batches should therefore include a factorial design at three compression forces and two pre-compression speeds.

The as-supplied veterinary API powder should not be assumed suitable for direct dissolution into an injectable solution. Injectable dosage forms require a low bioburden, controlled endotoxin content, and sub-visible particulate limits that are not automatically met by a non-sterile powder. For each injectable development batch, the API is dissolved in Water for Injections, the pH is adjusted with a pharmacopoeial acid or base, and the solution is clarified by serial filtration through a 0.45 µm prefilter and a 0.22 µm sterilising-grade membrane. Terminal sterilisation by autoclaving at 121 °C for 15 min is acceptable only if forced-degradation studies demonstrate that the active ingredient remains within the defined degradation threshold. If the molecule is heat-labile, aseptic filtration is used. Sterility of the finished injection is confirmed by Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins by Ph. Eur. 2.6.14 or USP <85>, and particulate matter by Ph. Eur. 2.9.19 or USP <788>. The API batch specification must include an endotoxin limit consistent with the intended maximum dose; if the maximum dose is not established, the limit should be derived from the formula K/M where K is 5 EU/kg for intravenous veterinary products and M is the maximum dose in kg per hour.

What Limits Direct Use of Unmodified Powder in Injectable Solutions?

Three physical and chemical factors limit direct use of the unmodified powder in injectable solutions. First, the particle size distribution of an oral-grade powder may be too coarse for rapid dissolution; dissolution rate is inversely related to particle size according to the Noyes-Whitney equation, and reduction to a d90 below 10 µm may be required for poorly soluble active ingredients. Second, trace residual solvents from the final crystallisation step may remain in the API and must comply with VICH GL18 limits; for an injectable product, a more stringent Class 1 solvent limit may be required. Third, the oxidative stability of the dissolved API must be evaluated under nitrogen blanketing and antioxidant addition; if no stabilising excipient is acceptable, the solution may need to be lyophilised. Published stability data for Longxiao Powder in injectable solution are limited, so forced degradation studies at 40 °C/75 % RH and 2–8 °C are necessary before a formulation is locked.

In medicated premix applications, the powder is blended with a feed carrier such as ground corn or wheat middlings. The primary technical risk is segregation because the active powder may have a smaller particle size and higher density than the carrier. Premix homogeneity is assessed by sampling from 10 defined locations, including the mixer dead zone, and assaying with a validated HPLC method. The coefficient of variation for active content should be not more than 5.0 %, but the registered product specification may set a tighter limit for low-inclusion premixes. If the active is added at 1 kg/tonne or less, a stepwise dilution sequence is used: first a 1:10 pre-blend, then a second 1:10 dilution into the final carrier. Mixer validation is conducted according to ISO 6497:2002 for sampling and the relevant feed assay method. Carry-over from a previous batch should be below 1.0 % of the target active level unless a dedicated line is used.

Premix Homogeneity and Segregation Control in Dry Feed Matrices

Segregation in a finished premix is controlled not only by blending time but also by particle size matching between the active powder and the carrier. If the API has a d50 below 50 µm and the carrier has a d50 above 300 µm, the active may concentrate in the fines fraction during transfer and discharge. In such cases, a small amount of a high-purity vegetable oil or mineral oil may be applied at 0.5–1.5 % w/w to reduce dusting and improve adhesion, but the selected oil must be compatible with the target species and the final feed matrix. The mixer speed and fill ratio must be validated using replicate batches assayed according to the registered feed method. For granular premix products, the powder may be agglomerated in a high-shear granulator with an impeller speed of 200–400 rpm and a chopper speed of 1,500–3,000 rpm; these ranges are equipment-dependent and should be confirmed on the specific granulator. Drying in a fluidised-bed dryer with an inlet air temperature of 50–60 °C is typically used until loss on drying is below 2.0 %. The final granule fraction should be retained on a 0.150 mm sieve but pass a 0.850 mm sieve to meet common feed premix handling requirements. If published data for Longxiao Powder in feed matrices are limited, a pilot-scale mixing study with 3 consecutive batches is the minimum basis for setting a registered mixing time.

Differences from Technical-Grade and Sterile API Powders

Compared with technical-grade or feed-grade material, Longxiao Powder Veterinary Grade API is controlled against pharmaceutical identity and purity tests, not only assay and heavy metals. A feed-additive powder may be acceptable in a simple premix but lacks the bioburden, endotoxin, and residual solvent data required for injectable or intramammary formulations. Conversely, a sterile injectable API is not automatically interchangeable with the veterinary grade powder because the sterile grade must be depyrogenated, aseptically crystallised, and released with a sterility certificate. The veterinary grade powder is therefore positioned between technical-grade material and sterile injectable material: it is suitable for oral solid dosage forms, non-sterile powders, granules, and premixes, and can be further processed into injectable solutions only after additional purification, filtration, and sterility assurance steps.

A solvent-based manufacturing route for Longxiao Powder requires a different release emphasis than dry mixing. The API is dissolved in a pharmacopoeial solvent such as purified water, ethanol, or propylene glycol, and the resulting solution is incorporated into an oral liquid, a soluble powder, or a drinking-water formulation. The powder must be assayed for water-soluble and solvent-soluble impurities because these species may remain in solution and affect stability. Clarity of the final solution is assessed by visual inspection, and filtration through a 0.45 µm membrane is commonly used for non-sterile oral liquids. If the solution is intended for drinking-water administration, the API must be stable in aqueous vehicle for at least 24 h at ambient temperature unless the product is prepared immediately before administration. The choice of salt form or co-solvent should be based on solubility screening across pH 3.0–9.0. Published data for this specific solvent configuration are limited; stability-indicating HPLC method development is therefore the first formulation step before selecting a co-solvent system.

Should the API Be Reclassified for Solvent-Based Solution Manufacturing?

No reclassification is required solely because the powder is intended for solution manufacturing, but the batch record should document residual solvent content, solubility, and moisture. A veterinary API powder with a high residual water content may be unsuitable for moisture-sensitive packaging or for non-aqueous solutions because water can accelerate hydrolysis or reduce chemical stability. In practice, the powder is dried to a loss on drying value below 1.0 % if the solution vehicle is non-aqueous. However, if the API is subsequently processed into granules or premix, a moisture content of 2.0 % may be acceptable because the carrier and final package can tolerate the residual water. The formulator should not transfer a specification limit from one dosage form to another without stability data, because the route of administration, dose, and excipient environment change the acceptable residual solvent and water limits. For tablets and capsules, the primary concern is solid-state stability and flow; for injections, the primary concern is endotoxin and particulate matter; for premixes, the primary concern is homogeneity and segregation. These differences mean that Longxiao Powder Veterinary Grade API is not a single-specification material for all applications but a pharmaceutical-grade starting material whose final release limits must be aligned with the specific dosage form and manufacturing route.